Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

40.95 -0.73 (-1.76%)
Streaming Delayed Price Updated: 3:01 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Exelixis, Inc.
Via Business Wire
News headline image
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock ↗
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
News headline image
More Chinese Trouble ↗
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
News headline image
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
From Exelixis, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
News headline image
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation ↗
The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers... 
Via Benzinga
News headline image
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2% ↗
Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after recording losses in the previous session. Investors are awaiting earnings results from... 
Via Benzinga
News headline image
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery ↗
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal... 
Via Benzinga
News headline image
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
Both have underperformed the market recently. And both are primed for a comeback. 
Via The Motley Fool
News headline image
Exelixis Statement on the Passing of Two Senior Executives
From Exelixis, Inc.
Via Business Wire
News headline image
Is Exelixis Stock a Buy? ↗
This biotech stock is down, but it's not out just yet. 
Via The Motley Fool
News headline image
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer ↗
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received... 
Via Benzinga
News headline image
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9... 
Via Benzinga
News headline image
Exelixis, Invenra Expand Oncology Pact ↗
Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented... 
Via Benzinga
News headline image
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript ↗
EXEL earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Recap: Exelixis Q2 Earnings ↗
Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Sensus Healthcare (NASDAQ:SRTS) ... 
Via Benzinga
News headline image
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer ↗
The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid... 
Via Benzinga
News headline image
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
5 No-Brainer Stocks to Invest $500 In Right Now ↗
You don't need a mountain of cash to build wealth on Wall Street. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.